RU2018141866A - КОМПОЗИЦИЯ ДЛЯ СТИМУЛИРОВАНИЯ СОЗРЕВАНИЯ ДЕНДРИТНЫХ КЛЕТОК, СОДЕРЖАЩАЯ ГИБРИДНЫЙ БЕЛОК Rv2299c/ESAT-6 - Google Patents
КОМПОЗИЦИЯ ДЛЯ СТИМУЛИРОВАНИЯ СОЗРЕВАНИЯ ДЕНДРИТНЫХ КЛЕТОК, СОДЕРЖАЩАЯ ГИБРИДНЫЙ БЕЛОК Rv2299c/ESAT-6 Download PDFInfo
- Publication number
- RU2018141866A RU2018141866A RU2018141866A RU2018141866A RU2018141866A RU 2018141866 A RU2018141866 A RU 2018141866A RU 2018141866 A RU2018141866 A RU 2018141866A RU 2018141866 A RU2018141866 A RU 2018141866A RU 2018141866 A RU2018141866 A RU 2018141866A
- Authority
- RU
- Russia
- Prior art keywords
- rv2299c
- esat
- maturation
- dendritic cells
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/45—Bacterial antigens
- A61K40/4524—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (12)
1. Композиция для индукции созревания дендритных клеток, при этом указанная композиция содержит гибридный белок Rv2299c/ESAT-6 в качестве активного ингредиента.
2. Композиция по п. 1, отличающаяся тем, что указанный гибридный белок Rv2299c/ESAT-6 представляет собой белок, полученный из М. tuberculosis.
3. Композиция по п. 1, отличающаяся тем, что указанный гибридный белок Rv2299c/ESAT-6 содержится в концентрации от 1 мкг/мл до 20 мкг/мл.
4. Способ индукции созревания незрелых дендритных клеток, включающий:
(a) осуществление дифференцировки мононуклеарных клеток, выделенных из крови, в незрелые дендритные клетки; и
(b) осуществление обработки указанных незрелых дендритных клеток гибридным белком Rv2299c/ESAT-6 для обеспечения созревания указанных незрелых дендритных клеток в зрелые дендритные клетки.
5. Способ по п. 4, отличающийся тем, что после обработки указанных незрелых дендритных клеток гибридным белком Rv2299c/ESAT-6 указанные клетки культивируют от 12 часов до 36 часов.
6. Способ по п. 4, отличающийся тем, что указанный гибридный белок Rv2299c/ESAT-6 увеличивает продукцию по меньшей мере одного белка, выбранного из группы, состоящей из TNF-α, IL-12p70, IL-6 и IL-lβ, во время созревания незрелых дендритных клеток.
7. Способ по п. 4, отличающийся тем, что указанный гибридный белок Rv2299c/ESAT-6 содержится в концентрации от 1 мкг/мл до 20 мкг/мл.
8. Способ по п. 4, отличающийся тем, что созревание указанных незрелых дендритных клеток вызвано стимуляцией TLR (toll-подобного рецептора)-4 гибридным белком Rv2299c/ESAT-6.
9. Способ по п. 4, отличающийся тем, что созревание незрелых дендритных клеток вызвано стимуляцией митоген-активируемой протеинкиназы (МАРК) и NF-κB.
10. Композиция для усиления иммунитета, при этом указанная композиция содержит композицию по п. 1 или 2.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2016-0070517 | 2016-06-07 | ||
| KR1020160070517A KR101749165B1 (ko) | 2016-06-07 | 2016-06-07 | Rv2299c 또는 Rv2299c와 ESAT-6 융합한 단백질을 포함하는 수지상 세포의 성숙화 촉진용 조성물 |
| PCT/KR2017/005892 WO2017213407A1 (ko) | 2016-06-07 | 2017-06-07 | Ｒｖ２２９９ｃ와 ＥＳＡＴ-６ 융합한 단백질을 포함하는 수지상 세포의 성숙화 촉진용 조성물 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018141866A3 RU2018141866A3 (ru) | 2020-07-10 |
| RU2018141866A true RU2018141866A (ru) | 2020-07-10 |
| RU2733886C2 RU2733886C2 (ru) | 2020-10-07 |
Family
ID=59283477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018141866A RU2733886C2 (ru) | 2016-06-07 | 2017-06-07 | КОМПОЗИЦИЯ ДЛЯ СТИМУЛИРОВАНИЯ СОЗРЕВАНИЯ ДЕНДРИТНЫХ КЛЕТОК, СОДЕРЖАЩАЯ ГИБРИДНЫЙ БЕЛОК Rv2299c/ESAT-6 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11414646B2 (ru) |
| EP (1) | EP3467102B1 (ru) |
| JP (1) | JP6683892B2 (ru) |
| KR (1) | KR101749165B1 (ru) |
| CN (1) | CN109415700B (ru) |
| AU (1) | AU2017279377B2 (ru) |
| BR (1) | BR112018075291A2 (ru) |
| MX (1) | MX391634B (ru) |
| PH (1) | PH12018502533A1 (ru) |
| RU (1) | RU2733886C2 (ru) |
| WO (1) | WO2017213407A1 (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102193304B1 (ko) * | 2019-10-24 | 2020-12-22 | 충남대학교산학협력단 | Rv2299c-ESAT6-HspX-RipA 융합단백질의 BCG 백신 booster용 조성물 |
| KR102878370B1 (ko) * | 2022-06-17 | 2025-10-31 | 주식회사 미코라파 | 면역활성 부위 융합 단백질을 포함하는 결핵 백신 조성물 |
| KR20250057173A (ko) | 2023-10-18 | 2025-04-29 | 주식회사 큐라티스 | 결핵 예방용 mRNA 백신 조성물 |
| KR20250087737A (ko) * | 2023-12-06 | 2025-06-17 | 주식회사 미코라파 | 결핵균에 대한 살균면역을 유도하는 융합단백질을 포함하는 결핵 백신 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060057120A1 (en) * | 2002-12-06 | 2006-03-16 | Northwest Biotherapeutics Inc. | Administration of dendritic cells partially matured in vitro for the treatment of tumors |
| US8273357B2 (en) * | 2004-07-16 | 2012-09-25 | Massachusetts Institute Of Technology | Antigen-carbohydrate conjugates |
| CN102149822A (zh) | 2008-09-12 | 2011-08-10 | 株式会社Lg生命科学 | 用于检测结核分枝杆菌复合群或分枝杆菌属的组合物和使用所述组合物通过多重实时pcr来同时检测结核分枝杆菌复合群和分枝杆菌属的方法 |
| KR101158649B1 (ko) | 2010-05-27 | 2012-06-26 | 울산대학교 산학협력단 | 이중 실시간 중합효소연쇄반응법을 이용한 결핵균과 항산성비결핵균의 검출 방법 |
| KR20120068647A (ko) * | 2010-12-18 | 2012-06-27 | 아이진 주식회사 | 개선된 면역반응을 유도하는 백신 |
| JP5906019B2 (ja) | 2011-03-31 | 2016-04-20 | 国立大学法人福井大学 | 免疫刺激ｇ９．１の抗結核ブースターワクチン創出への応用 |
| KR101264821B1 (ko) * | 2011-07-25 | 2013-05-15 | 충남대학교산학협력단 | 결핵균의 Ｒｖ０５７７ 단백질을 이용한 수지상 세포의 성숙방법 |
| KR101270999B1 (ko) * | 2011-10-11 | 2013-06-04 | 충남대학교산학협력단 | 결핵균의 Ｒｖ２２９９ｃ 단백질을 이용한 수지상 세포의 성숙방법 |
| KR101403507B1 (ko) | 2013-03-21 | 2014-06-09 | 주식회사 현일바이오 | 결핵균 및 비결핵 마이코박테리아의 선택적 검출 방법, 그리고 이를 이용한 키트 |
-
2016
- 2016-06-07 KR KR1020160070517A patent/KR101749165B1/ko active Active
-
2017
- 2017-06-07 JP JP2019517746A patent/JP6683892B2/ja active Active
- 2017-06-07 EP EP17810530.0A patent/EP3467102B1/en active Active
- 2017-06-07 RU RU2018141866A patent/RU2733886C2/ru active
- 2017-06-07 WO PCT/KR2017/005892 patent/WO2017213407A1/ko not_active Ceased
- 2017-06-07 BR BR112018075291-6A patent/BR112018075291A2/pt not_active Application Discontinuation
- 2017-06-07 AU AU2017279377A patent/AU2017279377B2/en active Active
- 2017-06-07 MX MX2018015224A patent/MX391634B/es unknown
- 2017-06-07 CN CN201780035376.8A patent/CN109415700B/zh active Active
-
2018
- 2018-11-29 PH PH12018502533A patent/PH12018502533A1/en unknown
- 2018-11-29 US US16/204,436 patent/US11414646B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX391634B (es) | 2025-03-21 |
| BR112018075291A2 (pt) | 2019-04-30 |
| CN109415700B (zh) | 2022-04-08 |
| MX2018015224A (es) | 2019-03-28 |
| AU2017279377B2 (en) | 2020-04-30 |
| JP6683892B2 (ja) | 2020-04-22 |
| EP3467102A4 (en) | 2019-08-28 |
| RU2018141866A3 (ru) | 2020-07-10 |
| US11414646B2 (en) | 2022-08-16 |
| AU2017279377A1 (en) | 2018-12-20 |
| EP3467102B1 (en) | 2021-09-15 |
| JP2019521183A (ja) | 2019-07-25 |
| CN109415700A (zh) | 2019-03-01 |
| US20190153390A1 (en) | 2019-05-23 |
| EP3467102A1 (en) | 2019-04-10 |
| KR101749165B1 (ko) | 2017-06-23 |
| RU2733886C2 (ru) | 2020-10-07 |
| WO2017213407A1 (ko) | 2017-12-14 |
| PH12018502533A1 (en) | 2019-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018141866A (ru) | КОМПОЗИЦИЯ ДЛЯ СТИМУЛИРОВАНИЯ СОЗРЕВАНИЯ ДЕНДРИТНЫХ КЛЕТОК, СОДЕРЖАЩАЯ ГИБРИДНЫЙ БЕЛОК Rv2299c/ESAT-6 | |
| Borriello et al. | Identification and characterization of stimulator of interferon genes as a robust adjuvant target for early life immunization | |
| MX382541B (es) | Métodos para aislar, cultivar y diseñar genéticamente poblaciones de células inmunes para terapia adoptiva. | |
| WO2015154012A8 (en) | Clonogenic natural killer (nk) cell populations and methods of producing and using such populations | |
| Zaal et al. | Crosstalk between Toll like receptors and C5a receptor in human monocyte derived DCs suppress inflammatory cytokine production | |
| HK1211620A1 (en) | Natural killer cells and uses thereof | |
| Rodríguez-Gómez et al. | Expression of T-bet, Eomesodermin and GATA-3 in porcine αβ T cells | |
| AU2017285758A1 (en) | Method for improving salt tolerance of plant | |
| MX2013014485A (es) | Vacuna bovinas y metodos. | |
| EP4316497A3 (en) | Mesenchymal stem cells as vaccine adjuvants and methods for using the same | |
| EA201790680A1 (ru) | Вакцины против вируса иммунодефицита человека (вич), содержащие один или более эписенсусных (episensus) для популяции антигенов | |
| RU2016116988A (ru) | Вакцина против haemophilus parasuis серологического типа 4 | |
| EA201400216A1 (ru) | Консервирование биологических продуктов, в частности вакцин, с применением вакуума | |
| RU2012148391A (ru) | СПОСОБЫ ИДЕНТИФИКАЦИИ, ВЫДЕЛЕНИЯ, ИСТОЩЕНИЯ И ОБОГАЩЕНИЯ ПОПУЛЯЦИЙ Tr1 КЛЕТОК, ПОПУЛЯЦИИ Tr1 КЛЕТОК, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СПОСОБ МОНИТОРИНГА ЭФФЕКТА ТЕРАПИИ | |
| WO2012118349A3 (ko) | 제대혈 ｃｄ14 양성 단핵세포로부터 자연살해세포 분화 및 증식 방법 | |
| NZ614634A (en) | Compositions and methods for separating, characterizing and administering soluble selenoglycoproteins | |
| PL4063491T3 (pl) | Kompozycja do hodowli komórek naturalnych zabójców i sposób otrzymywania komórek naturalnych zabójców z jej zastosowaniem | |
| MX2023001622A (es) | Celulas dendriticas optimamente activadas que inducen una respuesta inmunologica antitumoral mayor o mejorada. | |
| CN106802347A (zh) | 一种检测外周血乙肝表面抗体分泌细胞的方法 | |
| MD4284B1 (ru) | Способ кормления пчелиных семей | |
| WO2018155952A3 (ko) | 인간 뇌 조직 유래 신경줄기세포의 고효율 분리 방법 | |
| TH1801007554A (th) | องค์ประกอบสำหรับส่งเสริมการเจริญเต็มที่ของเซลล์เดนดริติกที่มีฟิวชันโปรตีน Rv2299c และ ESAT-6 | |
| RU2010122345A (ru) | Композиции и способы применения белка са9 для стимуляции иммунного ответа | |
| Wagner et al. | Soluble and Exosome-Bound α-Galactosylceramide Mediate Preferential Proliferation of Educated NK Cells with Increased Anti-Tumor Capacity. Cancers 2021, 13, 298 | |
| Costantini et al. | On the co-purification of 6-sulfo LacNAc+ dendritic cells (slanDC) with NK cells enriched from human blood |